open access

Vol 51, No 2 (2013)
Original paper
Submitted: 2013-02-06
Accepted: 2013-05-27
Published online: 2013-08-02
Get Citation

Ceramide galactosyltransferase (UGT8) as a molecular marker of canine mammary tumor malignancy

Marcin Nowak, Piotr Dziegiel, Janusz Madej, Maciej Ugorski
DOI: 10.5603/FHC.2013.0024
·
Folia Histochem Cytobiol 2013;51(2):164-167.

open access

Vol 51, No 2 (2013)
ORIGINAL PAPERS
Submitted: 2013-02-06
Accepted: 2013-05-27
Published online: 2013-08-02

Abstract

Thirty-two canine mammary tubulopapillary carcinomas and 14 simple adenomas were studied by immunohistochemistry for the expression of UDP-galactose:ceramide galactosyltransferase (UGT8). The majority of tissue specimens (57%) representing adenomas had no or weak reaction with anti-UGT8 antibodies (0-2 pts according to IRS scale) in comparison to the majority of carcinomas (90%) which stained with high intensities (3-9 pts according to IRS scale). When the average values of the reaction intensities (IRS) for malignant and benign tumors were compared, using the Mann-Whitney U-test, significant differences in UGT8 expression between them were found (P < 0.001). Mammary tubulopapillary carcinomas were further analyzed by IHC and the same rabbit polyclonal antibody directed against UGT8 according to their malignancy grade. It was found that the level of UGT8 increased in tumor specimens together with their grading. A comparison of the average values of the reaction intensity (IRS scale) revealed a significant difference (Mann-Whitney U-test, P < 0.05) in UGT8 expression between tumors representing malignancy grades G3 and G1. Based on the obtained results, it is proposed that UGT8 is associated with malignancy of canine mammary gland cells and may have a potential value as a diagnostic marker.

Abstract

Thirty-two canine mammary tubulopapillary carcinomas and 14 simple adenomas were studied by immunohistochemistry for the expression of UDP-galactose:ceramide galactosyltransferase (UGT8). The majority of tissue specimens (57%) representing adenomas had no or weak reaction with anti-UGT8 antibodies (0-2 pts according to IRS scale) in comparison to the majority of carcinomas (90%) which stained with high intensities (3-9 pts according to IRS scale). When the average values of the reaction intensities (IRS) for malignant and benign tumors were compared, using the Mann-Whitney U-test, significant differences in UGT8 expression between them were found (P < 0.001). Mammary tubulopapillary carcinomas were further analyzed by IHC and the same rabbit polyclonal antibody directed against UGT8 according to their malignancy grade. It was found that the level of UGT8 increased in tumor specimens together with their grading. A comparison of the average values of the reaction intensity (IRS scale) revealed a significant difference (Mann-Whitney U-test, P < 0.05) in UGT8 expression between tumors representing malignancy grades G3 and G1. Based on the obtained results, it is proposed that UGT8 is associated with malignancy of canine mammary gland cells and may have a potential value as a diagnostic marker.

Get Citation

Keywords

immunohistochemistry

About this article
Title

Ceramide galactosyltransferase (UGT8) as a molecular marker of canine mammary tumor malignancy

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 51, No 2 (2013)

Article type

Original paper

Pages

164-167

Published online

2013-08-02

DOI

10.5603/FHC.2013.0024

Bibliographic record

Folia Histochem Cytobiol 2013;51(2):164-167.

Keywords

immunohistochemistry

Authors

Marcin Nowak
Piotr Dziegiel
Janusz Madej
Maciej Ugorski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl